GMP has always been the backbone of pharmaceutical and biotech manufacturing, ensuring safety, quality, and consistency. But as the industry evolves, so does the way we think about GMP. 

Where is GMP headed? From AI and automation to workforce bandwidth and shifts in global manufacturing, the landscape is shifting quickly. RegDev’s GMP expert, Stanford Ma, shares his thoughts on the key trends shaping the future of manufacturing and why it matters for pharma and biotech.  

Global Supply and Tariffs

Tariffs and the realities of offshoring have impacted manufacturing over the past decade, but the trend we’re beginning to see is a return of manufacturing to the U.S. The FDA (U.S. Food and Drug Administration) is actively supporting this movement through guidance and by streamlining the pathway for regulatory approvals.  

Early communication between manufacturers and the FDA during planning, facility design, and quality-control stages will proactively resolve issues upfront rather than wait until PAI (Pre-Approval Inspection). The goal is to accelerate the approval process to increase domestic manufacturing capacities. 

AI and Automation

The integration of AI and automation into GMP systems will be transformative. Real-time virtual replicas of physical processes, equipment, or even an entire facility enables process simulation and optimization, operator training, and real-time process monitoring and control to reduce errors, improve efficiency, and strengthen compliance.  

Continuous processing, which is a shift from traditional batch processing (start-stop), features integrated systems to increase efficiency, quality consistency, and reduce production downtime. 

Regulatory agencies such as EMA (European Medicines Agency), WHO (World Health Organization), and FDA are standardizing remote and hybrid inspections, combining virtual document reviews with on-site visits.  VR (virtual reality) walkthroughs are being piloted to facilitate guided remote facility inspections. 

Data Integrity and Electronic Systems

Regulatory bodies are increasing their focus on data integrity.  Strong emphasis is placed on electronic systems (i.e., Enterprise Resource Planning, Laboratory Information Management System, Manufacturing Execution System, etc.) supporting GMP activities. Companies are being cited for issues associated with audit trail gaps and deletion of data (failed test results). 

Regulatory agencies such as FDA and EMA are endorsing electronic batch records, digital QMS (Quality Mangement Systems), and robust validation to ensure data integrity and traceability. 

Risk Assessment

In an increasingly complex landscape, GMP is not only about compliance but also about building a culture of risk-based thinking. Identifying, assessing, and mitigating risks proactively helps manufacturers maintain both compliance and quality across the different elements of the GMP systems. 

Bandwidth and Expertise

Perhaps the most pressing challenge is human capital. Many organizations face bandwidth constraints — either not enough staff, or not enough specialized expertise to fully support GMP implementation. Even the best technology won’t replace the need for skilled professionals who understand both the science and the regulations. 

As these forces converge, the future of GMP will likely blend innovation, regulatory alignment, and workforce development. For organizations, this means preparing not only with technology and infrastructure but also by investing in people and knowledge.